Efficacy, safety, and tolerability in patients switched to PEG (40 kDa) IFN α-2a (PEGASYS®) after discontinuation from interferon alfa-2b plus ribavirin (REBETRON™) combination therapy for chronic hepatitis C

but in females the incidence was twice that of males (12% vs. 6%, p=O.05).Two patients developed liver failure and died, one of whom was HBsAg positive at screening.Conclusion: In this study, a high incidence of severe liver toxicity was observed, especially in women.Clinically these events were attributed to NVP in combination with d4T and blinded treatment medication.Consistent with recent recommendations, liver enzymes in patients receiving NVP with other antiretrovirals should he monitored closely, particularly during the first eight weeks. 288O